Helicobacter pylori and benign upper digestive disease

Lai, Lihui; Sung, Joseph J.Y.

doi:10.1016/j.bpg.2006.10.002

Cited by 26 publications

(18 citation statements)

References 115 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The European Helicobacter Study Group (EHSG) was founded in 1987 to promote multidisciplinary research into the pathogenesis of H. pylori as a cause of upper gastrointestinal tract diseases, and how the treatment of H. pylori will aid in the prevention of gastric cancer (16).The EHSG has organized many annual consensus meetings and published current concepts regarding the management of H. pylori infection in Maastricht I, II, III and Maastricht IV (18,19,20).…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori Infection and Undiagnosed Dyspepsia in Dyspeptic Populations Under 45 of Age Tested by ELISA, Urease Breath Test and Helicotest

Palka¹

2012

Serological Diagnosis of Certain Human, Animal and Plant Diseases

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori Infection and Undiagnosed Dyspepsia in Dyspeptic Populations Under 45 of Age Tested by ELISA, Urease Breath Test and Helicotest

Palka¹

2012

Serological Diagnosis of Certain Human, Animal and Plant Diseases

View full text Add to dashboard Cite

“…Results have been inconclusive, and a direct relationship between the two has not been found. [60,61] Furthermore, the presence of H. pylori has not been found to affect the performance of currently available PPIs. [62] Unlike the bacteria recently found in the oral cavity and upper gastrointestinal tract, however, H. pylori does not produce acid and subsequently does not contain a proton pump.…”

Section: Acid-producing Bacteriamentioning

confidence: 99%

Gastroesophageal Reflux Disease (GERD): Is There More to the Story?

et al. 2008

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD) affects both men and women worldwide, with the most common symptom of GERD being frequent heartburn. If left untreated, more serious diseases including esophagitis and/or esophageal cancer may result. GERD has been commonly held to be the result of gastric acid refluxing into the esophagus. Recent work, however, has shown that there are acid-producing cells in the upper aerodigestive tract. In addition, acid-producing bacteria located within the upper gastrointestinal tract and oral cavity may also be a contributing factor in the onset of GERD. Proton pump inhibitors (PPIs) are commonly prescribed for treating GERD; these drugs are designed to stop the production of gastric acid by shutting down the H(+)/K(+)-ATPase enzyme located in parietal cells. PPI treatment is systemic and therefore significantly different than traditional antacids. Although a popular treatment choice, PPIs exhibit substantial interpatient variability and commonly fail to provide a complete cure to the disease. Recent studies have shown that H(+)/K(+)-ATPases are expressed in tissues outside the stomach, and the effects of PPIs in these nongastric tissues have not been fully explored. Likewise, acid-producing bacteria containing proton pumps are present in both the oral cavity and esophagus, and PPI use may also adversely affect these bacteria. The use of PPI therapy is further complicated by the two philosophical approaches to treating this disease: to treat only symptoms or to treat continuously. The latter approach frequently results in unwanted side effects which may be due to the PPIs acting on nongastric tissues or the microbes which colonize the upper aerodigestive tract.

show abstract

“…The symptoms of dyspepsia occur with similar frequency in those with and without a H. pylori infection. In addition, an eradication therapy commonly cannot eliminate the symptoms (40).…”

Section: H P Y L O R I a S S O C I A T E D D I S E A S E Smentioning

confidence: 99%